Piper Sandler reaffirmed its positive stance on Inspire Medical Systems (NYSE:NYSE:INSP), maintaining an Overweight rating with a $260.00 price target. The endorsement comes after a steep 14.15% ...

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

You don’t realize that you could be sleeping for eight hours but when you get tested you actually only slept for one or two.” ...

Following the evaluation of projects that advanced to the final stage and underwent the implementation phase, winners were selected based on criteria including creativity ... aims to broaden its ...

Obstructive sleep apnea (OSA) is when you briefly stop breathing ... Healthline has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical ...

Our take: The Fitbit Inspire 3 is a great sleep tracker for someone who wants to measure physical activity and sleep data without a bulky device on their wrist. This Fitbit’s sleek design ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.